{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:05:53Z","timestamp":1779318353155,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Hypertonie ist eine sehr h\u00e4ufige Komorbidit\u00e4t bei Diabetes mellitus, die \u2013\u00a0wenn unzureichend behandelt\u00a0\u2013 signifikant zur erh\u00f6hten Mortalit\u00e4t und zum Auftreten von mikrovaskul\u00e4ren und makrovaskul\u00e4ren Komplikationen beitr\u00e4gt. Blutdruckzielwerte um 120\u2013129\/70\u201379\u202fmm\u202fHg waren in den Studien mit der besten Prognose assoziiert, wobei die Blutdruckzielwerte je nach Alter und Komorbidit\u00e4ten individualisiert werden sollten; besonders wichtig ist, dass ein Blutdruck &lt;\u202f140\/90\u202fmm\u202fHg erreicht wird. F\u00fcr die meisten Menschen mit Diabetes ist eine Kombinationstherapie notwendig, wobei Medikamente mit gut evidenzbasierter Reduktion des kardiovaskul\u00e4ren Risikos (neben ACE-Hemmern und Angiotensinrezeptorblockern Dihydropyridin-Calciumantagonisten und Thiaziddiuretika) eingesetzt werden sollten, pr\u00e4ferenziell als Kombinationspr\u00e4parate. Nach Erreichung der Zielwerte muss die antihypertensive Therapie fortgef\u00fchrt werden, wobei regelm\u00e4\u00dfige Selbstmessungen des Blutdrucks f\u00fcr die Optimierung der Blutdruckeinstellung sehr hilfreich sind. SGLT-2-Inhibitoren oder GLP-1-Rezeptoragonisten tragen ebenfalls zur Blutdrucksenkung bei Diabetes bei. Dies gilt auch f\u00fcr den seit der letzten Auflage der Leitlinien neu verf\u00fcgbaren kombinierten GLP-1\/GIP-Rezeptoragonisten Tirzepatid. Seit der letzten Auflage der Leitlinien zeigten Interventionsstudien Vorteile einer intensiveren Blutdrucksenkung bei Typ-2-Diabetes, was sich in den aktuellen Leitlinien internationaler Gesellschaften widerspiegelt und auch in die vorliegenden Empfehlungen \u00fcbernommen wird; die Individualisierung der Blutdrucktherapie bleibt aber eine Kernempfehlung der \u00d6sterreichischen Diabetes-Gesellschaft.<\/jats:p>","DOI":"10.1007\/s00508-026-02719-7","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:26Z","timestamp":1779315386000},"page":"186-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Individualisierung der antihypertensiven Therapie bei Diabetes mellitus. Leitlinie der \u00d6sterreichischen Diabetes Gesellschaft (Update 2026)","Individualizing antihypertensive therapy in diabetes mellitus. Guidelines of the Austrian Diabetes Association (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Christoph H.","family":"Saely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna Maria","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Klauser-Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guntram","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"38","key":"2719_CR1","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy\u00a0JW, McCarthy\u00a0CP, Bruno\u00a0RM, Brouwers\u00a0S, Canavan\u00a0MD, Ceconi\u00a0C, et\u00a0al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European heart journal. 2024;45(38):3912\u20134018.","journal-title":"European heart journal"},{"issue":"19","key":"2719_CR2","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton\u00a0PK, Carey\u00a0RM, Aronow\u00a0WS, Casey\u00a0DE Jr, Collins\u00a0KJ, Himmelfarb C\u00a0D, et\u00a0al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J\u00a0Am Coll Cardiol. 2018;71(19):e127\u2013e248.","journal-title":"J Am Coll Cardiol"},{"key":"2719_CR3","doi-asserted-by":"crossref","unstructured":"Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes care. 2026;49(1 Suppl 1):S6\u2013S12.","DOI":"10.2337\/dc26-SDIS"},{"issue":"6","key":"2719_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMp1716193","volume":"378","author":"G Bakris","year":"2018","unstructured":"Bakris\u00a0G, Sorrentino\u00a0M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018;378(6):497\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"2719_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jacc.2017.11.029","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli\u00a0FH, Bangalore\u00a0S. Lowering the Thresholds of Diseases: Is Anyone Still Healthy? J\u00a0Am Coll Cardiol. 2018;71(2):119\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2719_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00125-017-4537-3","volume":"61","author":"G Mancia","year":"2018","unstructured":"Mancia\u00a0G, Grassi\u00a0G. Blood pressure targets in type 2 diabetes Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61(3):517\u201325.","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"2719_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00508-012-0270-6","volume":"124","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner\u00a0G, Drexel\u00a0H, Rosenkranz\u00a0AR, Schernthaner\u00a0GH, Watschinger\u00a0B. Antihypertensive therapy in diabetes mellitus - 2012 guidelines of the Austrian Diabetes Association. Wien Klin Wochenschr. 2012;124(Suppl 2):23\u20137.","journal-title":"Wien Klin Wochenschr"},{"issue":"Suppl 2","key":"2719_CR8","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1007\/s00508-015-0924-2","volume":"128","author":"G Schernthaner","year":"2016","unstructured":"Schernthaner\u00a0G, Drexel\u00a0H, Rosenkranz\u00a0A, Schernthaner\u00a0GH, Watschinger\u00a0B. Antihypertensive therapy in diabetes mellitus: Guidelines of the Austrian Diabetes Association 2016. Wien Klin Wochenschr. 2016;128(Suppl 2):S62\u2013S7.","journal-title":"Wien Klin Wochenschr"},{"issue":"Suppl\u00a01","key":"2719_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00508-019-1460-2","volume":"131","author":"G Schernthaner","year":"2019","unstructured":"Schernthaner\u00a0G, Saely\u00a0CH, Schernthaner\u00a0GH, Watschinger\u00a0B, Drexel\u00a0H. Individualising antihypertensive therapy in patients with diabetes. A\u00a0guideline by the Austrian Diabetes Association (Update 2019). Wiener klinische Wochenschrift. 2019;131(Suppl\u00a01):124\u201335.","journal-title":"Wiener klinische Wochenschrift"},{"issue":"9841","key":"2719_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini\u00a0E, Cushman\u00a0WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601\u201310.","journal-title":"Lancet"},{"issue":"6","key":"2719_CR11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCRESAHA.118.314487","volume":"124","author":"D Sun","year":"2019","unstructured":"Sun\u00a0D, Zhou\u00a0T, Heianza\u00a0Y, Li\u00a0X, Fan\u00a0M, Fonseca\u00a0VA, et\u00a0al. Type 2 Diabetes and Hypertension. Circ Res. 2019;124(6):930\u20137.","journal-title":"Circ Res"},{"issue":"7","key":"2719_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing\u00a0RR, Lang\u00a0W, Wadden\u00a0TA, Safford\u00a0M, Knowler\u00a0WC, Bertoni\u00a0AG, et\u00a0al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"2","key":"2719_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler\u00a0J, Vaccaro\u00a0O, Neaton\u00a0JD, Wentworth\u00a0D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434\u201344.","journal-title":"Diabetes Care"},{"issue":"7258","key":"2719_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler\u00a0AI, Stratton\u00a0IM, Neil\u00a0HA, Yudkin\u00a0JS, Matthews\u00a0DR, Cull\u00a0CA, et\u00a0al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):412\u20139.","journal-title":"BMJ (Clinical research ed)"},{"issue":"7","key":"2719_CR15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","volume":"53","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner\u00a0G, Barnett\u00a0AH, Betteridge\u00a0DJ, Carmena\u00a0R, Ceriello\u00a0A, Charbonnel\u00a0B, et\u00a0al. Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53(7):1258\u201369.","journal-title":"Diabetologia"},{"issue":"12","key":"2719_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi\u00a0Y, Li\u00a0M, Liu\u00a0Y, Li\u00a0T, Lu\u00a0J, Duan\u00a0P, et\u00a0al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. The New England journal of medicine. 2025;392(12):1155\u201367.","journal-title":"The New England journal of medicine"},{"issue":"10449","key":"2719_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","volume":"404","author":"J Liu","year":"2024","unstructured":"Liu\u00a0J, Li\u00a0Y, Ge\u00a0J, Yan\u00a0X, Zhang\u00a0H, Zheng\u00a0X, et\u00a0al. Lowering systolic blood pressure to less than 120\u202fmm Hg versus less than 140\u202fmm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet (London, England). 2024;404(10449):245\u201355.","journal-title":"Lancet (London, England)"},{"issue":"17","key":"2719_CR18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman\u00a0WC, Evans\u00a0GW, Byington\u00a0RP, Goff\u00a0DC Jr, Grimm\u00a0RH Jr, Cutler\u00a0JA, et\u00a0al. Effects of intensive blood-pressure control in type\u00a02 diabetes mellitus. The New England journal of medicine. 2010;362(17):1575\u201385.","journal-title":"The New England journal of medicine"},{"issue":"12","key":"2719_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2337\/dc17-1366","volume":"40","author":"LF Buckley","year":"2017","unstructured":"Buckley\u00a0LF, Dixon\u00a0DL, Wohlford\u00a0GF t, Wijesinghe\u00a0DS, Baker\u00a0WL, Van Tassell\u00a0BW. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care. 2017;40(12):1733\u20138.","journal-title":"Diabetes Care"},{"issue":"6","key":"2719_CR20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2337\/dc17-1722","volume":"41","author":"TF Brouwer","year":"2018","unstructured":"Brouwer\u00a0TF, Vehmeijer\u00a0JT, Kalkman\u00a0DN, Berger\u00a0WR, van den Born\u00a0BH, Peters\u00a0RJ, et\u00a0al. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials. Diabetes Care. 2018;41(6):1142\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"2719_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff\u00a0RM, Gong\u00a0Y, Handberg\u00a0EM, Bavry\u00a0AA, Denardo\u00a0SJ, Bakris\u00a0GL, et\u00a0al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. Jama. 2010;304(1):61\u20138.","journal-title":"Jama"},{"issue":"1","key":"2719_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2337\/dc10-1420","volume":"34","author":"RJ Anderson","year":"2011","unstructured":"Anderson\u00a0RJ, Bahn\u00a0GD, Moritz\u00a0TE, Kaufman\u00a0D, Abraira\u00a0C, Duckworth\u00a0W. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes care. 2011;34(1):34\u20138.","journal-title":"Diabetes care"},{"issue":"1","key":"2719_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL, Koskinas\u00a0KC, Casula\u00a0M, Badimon\u00a0L, et\u00a0al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020;41(1):111\u201388.","journal-title":"European heart journal"},{"issue":"5","key":"2719_CR24","first-page":"549","volume":"31","author":"SS Daskalopoulou","year":"2015","unstructured":"Daskalopoulou\u00a0SS, Rabi\u00a0DM, Zarnke\u00a0KB, Dasgupta\u00a0K, Nerenberg\u00a0K, Cloutier\u00a0L, et\u00a0al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015;31(5):549\u201368.","journal-title":"Can J Cardiol"},{"issue":"4","key":"2719_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2014.20","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto\u00a0K, Ando\u00a0K, Fujita\u00a0T, Hasebe\u00a0N, Higaki\u00a0J, Horiuchi\u00a0M, et\u00a0al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37(4):253\u2013390.","journal-title":"Hypertens Res"},{"key":"2719_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4891","volume":"343","author":"T Krause","year":"2011","unstructured":"Krause\u00a0T, Lovibond\u00a0K, Caulfield\u00a0M, McCormack\u00a0T, Williams\u00a0B. Management of hypertension: summary of NICE guidance. Bmj. 2011;343:d4891.","journal-title":"Bmj"},{"issue":"2 Suppl","key":"2719_CR27","first-page":"6","volume":"61","author":"Indian guidelines on hypertension (I.G.H.) - III","year":"2013","unstructured":"Indian guidelines on hypertension (I.G.H.) - III. Indian guidelines on hypertension (I.G.H.) - III. J\u00a0Assoc Physicians India. 2013;61(2 Suppl):6\u201336.","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"2719_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James\u00a0PA, Oparil\u00a0S, Carter\u00a0BL, Cushman\u00a0WC, Dennison-Himmelfarb\u00a0C, Handler\u00a0J, et\u00a0al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5):507\u201320.","journal-title":"Jama"},{"issue":"6","key":"2719_CR29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2337\/dci17-0063","volume":"41","author":"L-M JA","year":"2018","unstructured":"JA\u00a0L\u2011M, IH\u00a0B. Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes. Diabetes Care. 2018;41(6):1132\u20133.","journal-title":"Diabetes Care"},{"issue":"22","key":"2719_CR30","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright\u00a0JT Jr, Williamson\u00a0JD, Whelton\u00a0PK, Snyder\u00a0JK, Sink\u00a0KM, Rocco\u00a0MV, et\u00a0al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine. 2015;373(22):2103\u201316.","journal-title":"The New England journal of medicine"},{"issue":"6","key":"2719_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2337\/dc13-2334","volume":"37","author":"KL Margolis","year":"2014","unstructured":"Margolis\u00a0KL, O\u2019Connor\u00a0PJ, Morgan\u00a0TM, Buse\u00a0JB, Cohen\u00a0RM, Cushman\u00a0WC, et\u00a0al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"2719_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2213-8587(18)30099-8","volume":"6","author":"S Beddhu","year":"2018","unstructured":"Beddhu\u00a0S, Greene\u00a0T, Boucher\u00a0R, Cushman\u00a0WC, Wei\u00a0G, Stoddard\u00a0G, et\u00a0al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol. 2018;6(7):555\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9118","key":"2719_CR33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson\u00a0L, Zanchetti\u00a0A, Carruthers\u00a0SG, Dahlof\u00a0B, Elmfeldt\u00a0D, Julius\u00a0S, HOT Study Group, et\u00a0al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet (London, England). 1998;351(9118):1755\u201362.","journal-title":"Lancet (London, England)"},{"issue":"7160","key":"2719_CR34","first-page":"703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research ed). 1998;317(7160):703\u201313.","journal-title":"BMJ (Clinical research ed)"},{"issue":"24","key":"2719_CR35","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/eurheartj\/ehx809","volume":"39","author":"BA Bergmark","year":"2018","unstructured":"Bergmark\u00a0BA, Scirica\u00a0BM, Steg\u00a0PG, Fanola\u00a0CL, Gurmu\u00a0Y, Mosenzon\u00a0O, et\u00a0al. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart J. 2018;39(24):2255\u201362.","journal-title":"Eur Heart J"},{"issue":"9638","key":"2719_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann\u00a0JF, Schmieder\u00a0RE, McQueen\u00a0M, Dyal\u00a0L, Schumacher\u00a0H, Pogue\u00a0J, et\u00a0al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547\u201353.","journal-title":"Lancet"},{"issue":"1","key":"2719_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2011.09.040","volume":"59","author":"J Redon","year":"2012","unstructured":"Redon\u00a0J, Mancia\u00a0G, Sleight\u00a0P, Schumacher\u00a0H, Gao\u00a0P, Pogue\u00a0J, et\u00a0al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J\u00a0Am Coll Cardiol. 2012;59(1):74\u201383.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2719_CR38","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving\u00a0HH, Brenner\u00a0BM, McMurray\u00a0JJ, de Zeeuw\u00a0D, Haffner\u00a0SM, Solomon\u00a0SD, et\u00a0al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"2719_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","volume":"56","author":"MA Weber","year":"2010","unstructured":"Weber\u00a0MA, Bakris\u00a0GL, Jamerson\u00a0K, Weir\u00a0M, Kjeldsen\u00a0SE, Devereux\u00a0RB, et\u00a0al. Cardiovascular events during differing hypertension therapies in patients with diabetes. Journal of the American College of Cardiology. 2010;56(1):77\u201385.","journal-title":"Journal of the American College of Cardiology"},{"key":"2719_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12933-016-0391-8","volume":"15","author":"B Bohn","year":"2016","unstructured":"Bohn\u00a0B, Sch\u00f6fl\u00a0C, Zimmer\u00a0V, Hummel\u00a0M, Heise\u00a0N, Siegel\u00a0E, et\u00a0al. Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German\/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15:72\u201372.","journal-title":"Cardiovasc Diabetol"},{"key":"2719_CR41","doi-asserted-by":"crossref","unstructured":"Grenier J, Goodman SG, Leiter LA, Langer A, Teoh H, Bhatt DL, et\u00a0al. Blood Pressure Management in Adults With Type\u00a02 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Can J Diabetes. 2018;42(2):130\u20137.","DOI":"10.1016\/j.jcjd.2017.01.005"},{"issue":"23","key":"2719_CR42","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD, Pitt\u00a0B, Ruilope\u00a0LM, Rossing\u00a0P, et\u00a0al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"2719_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1524-6175.2005.04784.x","volume":"8","author":"R Qayyum","year":"2006","unstructured":"Qayyum\u00a0R, Adomaityte\u00a0J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J\u00a0Clin Hypertens (Greenwich). 2006;8(1):19\u201328.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"2719_CR44","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12085","volume":"15","author":"B Wang","year":"2013","unstructured":"Wang\u00a0B, Zhong\u00a0J, Lin\u00a0H, Zhao\u00a0Z, Yan\u00a0Z, He\u00a0H, et\u00a0al. Blood pressure-lowering effects of GLP\u20111 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737\u201349.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2719_CR45","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/dom.15529","volume":"26","author":"FB Rivera","year":"2024","unstructured":"Rivera\u00a0FB, Lumbang\u00a0GNO, Gaid\u00a0DRM, Cruz\u00a0LLA, Magalong\u00a0JV, Bantayan\u00a0NRB, et\u00a0al. Glucagon-like peptide\u20111 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes, obesity & metabolism. 2024;26(6):2209\u201328.","journal-title":"Diabetes, obesity & metabolism"},{"issue":"12","key":"2719_CR46","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1111\/dom.15272","volume":"25","author":"M Kanbay","year":"2023","unstructured":"Kanbay\u00a0M, Copur\u00a0S, Siriopol\u00a0D, Yildiz\u00a0AB, Gaipov\u00a0A, van Raalte\u00a0DH, et\u00a0al. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism. 2023;25(12):3766\u201378.","journal-title":"Diabetes, obesity & metabolism"},{"key":"2719_CR47","doi-asserted-by":"crossref","unstructured":"Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et\u00a0al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A\u00a0Systematic Review and Meta-Analysis. J\u00a0Am Heart Assoc. 2017;6(5).","DOI":"10.1161\/JAHA.117.005686"},{"issue":"22","key":"2719_CR48","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM, Fitchett\u00a0D, Bluhmki\u00a0E, Hantel\u00a0S, et\u00a0al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine. 2015;373(22):2117\u201328.","journal-title":"The New England journal of medicine"},{"issue":"7","key":"2719_CR49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffey\u00a0KW, de Zeeuw\u00a0D, Fulcher\u00a0G, Erondu\u00a0N, et\u00a0al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2719_CR50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, Raz\u00a0I, Bonaca\u00a0MP, Mosenzon\u00a0O, Kato\u00a0ET, Cahn\u00a0A, et\u00a0al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"2719_CR51","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00125-018-4547-9","volume":"61","author":"G Schernthaner","year":"2018","unstructured":"Schernthaner\u00a0G, Schernthaner-Reiter\u00a0MH. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia. 2018;61(7):1503\u201316.","journal-title":"Diabetologia"},{"issue":"14","key":"2719_CR52","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang\u00a0W, Zhang\u00a0S, Deng\u00a0Y, Wu\u00a0S, Ren\u00a0J, Sun\u00a0G, et\u00a0al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268\u201379.","journal-title":"N Engl J Med"},{"issue":"34","key":"2719_CR53","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM, Carballo\u00a0D, Koskinas\u00a0KC, B\u00e4ck\u00a0M, et\u00a0al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"3s","key":"2719_CR54","first-page":"S1","volume":"99","author":"KDIGO","year":"2021","unstructured":"KDIGO. 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3s):S1\u2013s87.","journal-title":"Kidney Int"},{"issue":"1","key":"2719_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","volume":"79","author":"I Dasgupta","year":"2022","unstructured":"Dasgupta\u00a0I, Zoccali\u00a0C. Is the KDIGO Systolic Blood Pressure Target \u3008\u202f120\u202fmm Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice? Hypertension. 2022;79(1):4\u201311.","journal-title":"Hypertension"},{"issue":"10","key":"2719_CR56","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1681\/ASN.2004110919","volume":"16","author":"MA Pohl","year":"2005","unstructured":"Pohl\u00a0MA, Blumenthal\u00a0S, Cordonnier\u00a0DJ, De Alvaro\u00a0F, Deferrari\u00a0G, Eisner\u00a0G, et\u00a0al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J\u00a0Am Soc Nephrol. 2005;16(10):3027\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2719_CR57","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller\u00a0H, Ito\u00a0S, Izzo\u00a0JL Jr, Januszewicz\u00a0A, Katayama\u00a0S, Menne\u00a0J, et\u00a0al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"2719_CR58","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1097\/HJH.0000000000001548","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos\u00a0C, Parati\u00a0G, Zanchetti\u00a0A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35(11):2138\u201349.","journal-title":"J Hypertens"},{"key":"2719_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","volume":"208","author":"XX Xie","year":"2016","unstructured":"Xie\u00a0XX, Liu\u00a0P, Wan\u00a0FY, Lin\u00a0SG, Zhong\u00a0WL, Yuan\u00a0ZK, et\u00a0al. Blood pressure lowering and stroke events in type 2 diabetes: A network meta-analysis of randomized controlled trials. Int J Cardiol. 2016;208:141\u20136.","journal-title":"Int J Cardiol"},{"issue":"36","key":"2719_CR60","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints\u00a0C, Andreotti\u00a0F, Koskinas\u00a0KC, Rossello\u00a0X, Adamo\u00a0M, Ainslie\u00a0J, et\u00a0al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European heart journal. 2024;45(36):3415\u2013537.","journal-title":"European heart journal"},{"issue":"1","key":"2719_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","volume":"202","author":"JA Dormandy","year":"2009","unstructured":"Dormandy\u00a0JA, Betteridge\u00a0DJ, Schernthaner\u00a0G, Pirags\u00a0V, Norgren\u00a0L. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). Atherosclerosis. 2009;202(1):272\u201381.","journal-title":"Atherosclerosis"},{"key":"2719_CR62","doi-asserted-by":"crossref","unstructured":"Sprenger L, Mader A, Larcher B, M\u00e4chler M, Vonbank A, Zanolin-Purin D, et\u00a0al. Type\u00a02 diabetes and the risk of cardiovascular events in peripheral artery disease versus coronary artery disease. BMJ Open Diabetes Res Care. 2021;9(2).","DOI":"10.1136\/bmjdrc-2021-002407"},{"issue":"1","key":"2719_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","volume":"55","author":"AA Bavry","year":"2010","unstructured":"Bavry\u00a0AA, Anderson\u00a0RD, Gong\u00a0Y, Denardo\u00a0SJ, Cooper-Dehoff\u00a0RM, Handberg\u00a0EM, et\u00a0al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR\/Trandolapril STudy. Hypertension. 2010;55(1):48\u201353.","journal-title":"Hypertension"},{"issue":"36","key":"2719_CR64","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai\u00a0L, Teixido-Tura\u00a0G, Lanzi\u00a0S, Boc\u00a0V, Bossone\u00a0E, Brodmann\u00a0M, et\u00a0al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. European heart journal. 2024;45(36):3538\u2013700.","journal-title":"European heart journal"},{"issue":"9","key":"2719_CR65","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh\u00a0M, Bidel\u00a0Z, Canoy\u00a0D, Copland\u00a0E, Bennett\u00a0DA, Dehghan\u00a0A, et\u00a0al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. The lancet Diabetes & endocrinology. 2022;10(9):645\u201354.","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"7","key":"2719_CR66","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41440-025-02209-9","volume":"48","author":"M Abe","year":"2025","unstructured":"Abe\u00a0M, Segawa\u00a0H, Kinguchi\u00a0S, Satoh\u00a0A, Zamami\u00a0R, Nishikido\u00a0T, et\u00a0al. Intensive blood pressure-lowering treatment to prevent cardiovascular events in patients with diabetes: a systematic review and meta-analysis. Hypertens Res. 2025;48(7):2024\u201333.","journal-title":"Hypertens Res"},{"issue":"5","key":"2719_CR67","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.117.10713","volume":"71","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal\u00a0R, Steinkamp\u00a0J, Chiu\u00a0N, Petrie\u00a0B, Mirzan\u00a0H. Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations: A\u00a0Pooled Individual Patient Data Analysis. Hypertension. 2018;71(5):833\u20139.","journal-title":"Hypertension"},{"issue":"5","key":"2719_CR68","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","volume":"35","author":"C Thomopoulos","year":"2017","unstructured":"Thomopoulos\u00a0C, Parati\u00a0G, Zanchetti\u00a0A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J\u00a0Hypertens. 2017;35(5):922\u201344.","journal-title":"J Hypertens"},{"issue":"10","key":"2719_CR69","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41371-018-0079-5","volume":"32","author":"E Papadopoulou","year":"2018","unstructured":"Papadopoulou\u00a0E, Angeloudi\u00a0E, Karras\u00a0S, Sarafidis\u00a0P. The optimal blood pressure target in diabetes mellitus: a\u00a0quest coming to an end? J\u00a0Hum Hypertens. 2018;32(10):641\u201350.","journal-title":"J Hum Hypertens"},{"key":"2719_CR70","unstructured":"Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053\u201364."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02719-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:16:30Z","timestamp":1779315390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":70,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2719"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02719-7","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.\u00a0Brix: Honorare f\u00fcr Advisory Board und Vortr\u00e4ge von Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk. R.\u00a0Klauser-Braun hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amgen, AstraZeneca, B\u00f6hringer Ingelheim, Lilly, Menarini, Novartis, Novo, Ratiopharm, Sanofi-Aventis. E.\u00a0Zitt hat in Bezug auf diesen Artikel von folgenden Unternehmen, die teils auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Bayer Austria, Boehringer Ingelheim, CSL Vifor, GSK, Novartis, Otsuka Pharmaceutical, SOBI, STADA, Vantive. C.H.\u00a0Saely, G.-H.\u00a0Schernthaner, H.\u00a0Drexel und G.\u00a0Schernthaner geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}